期刊
CURRENT UROLOGY REPORTS
卷 13, 期 1, 页码 16-23出版社
SPRINGER
DOI: 10.1007/s11934-011-0232-y
关键词
Targeted therapy; Sunitinib; Sorafenib; Everolimus; Temsirolimus; Pazopanib; Axitinib; Nephrectomy; Renal cell cancer; Kidneys
资金
- Roche
- Pfizer
During the past half-decade, clinical trials have permitted major progress in treatment of metastatic renal cell carcinoma with the first generation of targeted therapies (bevacizumab, sunitinib, sorafenib, everolimus, and temsirolimus). New targeted agents such as axitinib, tivozanib, and dovitinib, all of which are tyrosine kinase inhibitors, have been developed in treatment of metastatic renal cell carcinoma. In the same time, more information regarding mechanism of disease and drug resistance shed light on new targets and new potent agents. We report an overview of the more relevant data published over the past year, which may modify the therapeutic landscape of kidney cancer in the near future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据